Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.63 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.63 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL30718122 | 1.00 | CYP2C9 (0.63) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL22195036 | 0.86 | CYP2C9 (0.67) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL22191578 | 0.84 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL22191827 | 0.81 | CYP2C9 (0.60) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL27163520 | 0.81 | CYP2A6 (0.72) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL11837821 | 0.78 | CYP2A6 (0.68) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL10162470 | 0.78 | CYP2A6 (0.72) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL2121672 | 0.78 | CYP2A6 (1.00) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL2305968 | 0.78 | CYP2A6 (0.72) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 | |
| SCHEMBL3606928 | 0.77 | CYP2C9 (0.62) | CYP2C9CYP2C19CYP2A6CYP2B6CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2A6 4357/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2A6 4357/4885 |
| US-11845753-B2 | Inhibitors of menin-mll interaction | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2A6 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.